Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer

Clinical trial NCT06464692 · ACTIVE_NOT_RECRUITING

Trial details

NCT number

NCT06464692

Sponsor

AbbVie

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 1

Study type

INTERVENTIONAL

Start date

2024-09-30

Primary completion

2027-12-01

Enrollment

31

View on ClinicalTrials.gov